PHASE 2 STUDY DESIGN EVALUATING EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ANTI-CD40 MONOCLONAL ANTIBODY CFZ533 (ISCALIMAB) IN DE NOVO LIVER TRANSPLANT RECIPIENTS: THE CONTRAIL I STUDY
Publication
, Conference
Nashan, B; Knechtle, SJ; Saliba, F; Laessing, U; Espie, P; Klatt, J; Feng, S
Published in: TRANSPLANTATION
2020
Duke Scholars
Published In
TRANSPLANTATION
EISSN
1534-6080
ISSN
0041-1337
Publication Date
2020
Volume
104
Issue
9
Start / End Page
S89 / S89
Related Subject Headings
- Surgery
- 3204 Immunology
- 3202 Clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Nashan, B., Knechtle, S. J., Saliba, F., Laessing, U., Espie, P., Klatt, J., & Feng, S. (2020). PHASE 2 STUDY DESIGN EVALUATING EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ANTI-CD40 MONOCLONAL ANTIBODY CFZ533 (ISCALIMAB) IN DE NOVO LIVER TRANSPLANT RECIPIENTS: THE CONTRAIL I STUDY. In TRANSPLANTATION (Vol. 104, pp. S89–S89).
Nashan, Bjorn, Stuart J. Knechtle, Faouzi Saliba, Ute Laessing, Pascal Espie, Jan Klatt, and Sandy Feng. “PHASE 2 STUDY DESIGN EVALUATING EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ANTI-CD40 MONOCLONAL ANTIBODY CFZ533 (ISCALIMAB) IN DE NOVO LIVER TRANSPLANT RECIPIENTS: THE CONTRAIL I STUDY.” In TRANSPLANTATION, 104:S89–S89, 2020.
Nashan B, Knechtle SJ, Saliba F, Laessing U, Espie P, Klatt J, et al. PHASE 2 STUDY DESIGN EVALUATING EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ANTI-CD40 MONOCLONAL ANTIBODY CFZ533 (ISCALIMAB) IN DE NOVO LIVER TRANSPLANT RECIPIENTS: THE CONTRAIL I STUDY. In: TRANSPLANTATION. 2020. p. S89–S89.
Nashan, Bjorn, et al. “PHASE 2 STUDY DESIGN EVALUATING EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ANTI-CD40 MONOCLONAL ANTIBODY CFZ533 (ISCALIMAB) IN DE NOVO LIVER TRANSPLANT RECIPIENTS: THE CONTRAIL I STUDY.” TRANSPLANTATION, vol. 104, no. 9, 2020, pp. S89–S89.
Nashan B, Knechtle SJ, Saliba F, Laessing U, Espie P, Klatt J, Feng S. PHASE 2 STUDY DESIGN EVALUATING EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ANTI-CD40 MONOCLONAL ANTIBODY CFZ533 (ISCALIMAB) IN DE NOVO LIVER TRANSPLANT RECIPIENTS: THE CONTRAIL I STUDY. TRANSPLANTATION. 2020. p. S89–S89.
Published In
TRANSPLANTATION
EISSN
1534-6080
ISSN
0041-1337
Publication Date
2020
Volume
104
Issue
9
Start / End Page
S89 / S89
Related Subject Headings
- Surgery
- 3204 Immunology
- 3202 Clinical sciences
- 11 Medical and Health Sciences